Table 4.
EBOV GP-binding antibody GMCs in paediatric participants at 21 or 28 days post-dose 2, accounting for between-study variations (random intercept and random slope model).
| Age category | Study | GMC, EU/mL | 95% CI |
|---|---|---|---|
| Adolescentsa | Overall | 11,760 | 7827; 17,668 |
| EBL2002 | 13,307 | 10,824; 16,360 | |
| EBL2004 | 12,456 | 10,825; 14,332 | |
| EBL3001 stage 2 | 9812 | 8346; 11,535 | |
| Older childrenb | Overall | 14,557 | 9688; 21,872 |
| EBL2002 | 16,626 | 13,523; 20,440 | |
| EBL2004 | 16,331 | 14,251; 18,714 | |
| EBL3001 stage 2 | 11,361 | 9623; 13,412 | |
| Younger childrenc | Overall | 25,767 | 16,381; 40,528 |
| EBL2004 | 27,093 | 22,772; 32,234 | |
| EBL3001 stage 2 | 21,776 | 18,313; 25,892 |
CI; Confidence interval, EBOV GP; Ebola virus glycoprotein, EU; Enzyme-linked immunosorbent assay unit, GMC; Geometric mean concentration.
a
Participants aged 12–17 years in EBL2002, EBL2004, and EBL3001 stage 2.
b
Participants aged 4–11 years in EBL2002 and EBL3001 stage 2 and 5–11 years in EBL2004.
c
Participants aged 1–4 years in EBL2004 and 1–3 years in EBL3001 stage 2.